Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamahealthforum.2024.1356 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
340B Participation and Safety Net Engagement Among Federally Qualified Health Centers.
JAMA Health Forum
October 2024
Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis.
Importance: The 340B program provides discounts on outpatient drugs to certain hospitals and federally supported clinics (covered entities) that can be used to generate revenue to fund safety net care. While numerous studies have found no association between 340B and safety net care provision for most hospital covered entities, less is known about whether federally qualified health centers (FQHCs), the largest group of covered entities after hospitals, use the program to enhance safety net care.
Objective: To assess whether a proxy for 340B revenue was associated with increased safety net care provision among FQHCs.
Reforming 340B to Serve the Interests of Patients, Not Institutions.
JAMA Health Forum
July 2024
Pacific Research Institute, Pasadena, California.
Addressing financial toxicity in cancer treatment-An opportunity for the 340B drug pricing program.
Cancer
September 2024
Dow Division of Health Services Research, Department of Urology, University of Michigan, Ann Arbor, Michigan, USA.
Cancer treatment has become increasingly expensive, partially due to the use of specialty drugs. The costs of these drugs are often passed down to patients, who may face the consequences of paying for more than they can afford, leading to financial toxicity. The 340B drug pricing program is a health care policy that may provide an opportunity to mitigate the financial consequences of cancer care.
View Article and Find Full Text PDFOutcomes of the 340B Drug Pricing Program: A Scoping Review.
JAMA Health Forum
November 2023
Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Importance: The 340B Drug Pricing Program requires manufacturers to offer discounted drug prices to support safety net hospitals and clinics (covered entities) providing care to low-income populations. Amid expansion, the program has received criticism and calls for reform.
Objective: To assess the literature on the foundations of and outcomes associated with the 340B program.
340B-Where Do We Go From Here?
JAMA
August 2023
Program on Regulation, Therapeutics, and Law (PORTAL), Brigham and Women's Hospital, Boston, Massachusetts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!